Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00054730
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
2003-02-07
Brief Title:
Effects of CX516 on Functioning in Fragile X Syndrome and Autism
Sponsor:
RespireRx
Organization:
Cortex
Study Overview
Official Title:
Effects of Ampakine CX516 Ampalex on Functioning in Fragile X Syndrome and Autism
Status:
COMPLETED
Status Verified Date:
2005-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will investigate whether CX516 can improve attention memory language or behavior in adults with Fragile X Syndrome andor Autism
CX516 is an AMPAKINE compound AMPAKINE compounds enhance synaptic strength There is evidence to suggest that the synapses in the brain of an individual with fragile X syndrome are immature and abnormal It is possible CX516 may partially correct this synaptic transmission defect and lead to improvement in cognitive and behavioral functioning
There is also reason to believe that these changes caused by CX516 could be helpful in managing cognitive and behavioral symptoms in patients with autistic disorder
Involvement for each participant will last 28 days Participants will be given study medication a physical exam and a variety of cognitive assessment tests to study potential drug effectiveness at improving disease symptoms
CX516 is an AMPAKINE compound AMPAKINE compounds enhance synaptic strength There is evidence to suggest that the synapses in the brain of an individual with fragile X syndrome are immature and abnormal It is possible CX516 may partially correct this synaptic transmission defect and lead to improvement in cognitive and behavioral functioning
There is also reason to believe that these changes caused by CX516 could be helpful in managing cognitive and behavioral symptoms in patients with autistic disorder
Involvement for each participant will last 28 days Participants will be given study medication a physical exam and a variety of cognitive assessment tests to study potential drug effectiveness at improving disease symptoms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None